Skip to main content

Harvard Bio Stock Regains Lost Ground From Tumble Following Last Week s Q3 Report

NEW YORK, Nov. 3 (GenomeWeb News) - Shares in Harvard Bioscience closed up 6.56 percent on Wednesday, regaining ground lost since the company released lackluster revenue growth on Oct. 29.


The firm's shares closed up at $4.20 on the Nasdaq exchange, eclipsing the closing price for its shares just before it released its Q3 results on Oct. 29. The third-quarter earning sreport caused the company's shares to tumble 

more that 9 percent to close $3.70 on Oct. 29 from $4 the day before.


Last week, Harvard said its poorly performing Genomic Solutions unit acted as ballast on third-quarter revenue. The firm posted Q3 revenue of $23.2 million, up from $21.1 million in the comparable period a year ago. Harvard also lowered by $2.2 million its revenue outlook for the fourth quarter.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.